What do the latest studies say about bimatoprost for scalp hair growth?

For several years, bimatoprost has been known primarily as a treatment for glaucoma and, more recently, as a stimulant for eyelash growth. A newer question is gaining traction: can this compound also promote scalp hair growth? Research has begun to explore that, and the findings so far are early and mixed. Bimatoprost is a prostaglandin F2α analog, meaning it mimics substances the body produces naturally that have key functions in various tissues, including hair follicles. This compound became commercially famous under the name Latisse®, approved by the FDA in 2008 to promote eyelash growth. Its effect on the hair cycle then prompted medical interest in its potential use for alopecia, especially androgenetic alopecia, the most common form of hair loss in both men and women.

Most of the evidence comes from preclinical studies (in the laboratory or in animals) and early-stage clinical trials in humans. The most cited laboratory study is Khidhir and colleagues (2013, FASEB Journal), who applied bimatoprost to cultured human scalp follicles and to rodent pelage follicles. They reported that the drug stimulated the anagen phase (the active growth phase of hair) and that the effect appeared to be receptor-mediated. Those results were enough to justify testing in humans.

Allergan, the maker of Latisse, ran the scalp programme. Two phase 2 trials in men with androgenetic alopecia are registered on ClinicalTrials.gov: NCT01325337, which enrolled 307 men, and NCT01904721, which enrolled 244 men. NCT01325337 was randomized and triple-masked and compared three topical bimatoprost formulations against both a vehicle placebo and 5% minoxidil. Results for both trials were posted to the registry, but neither was published in a peer-reviewed journal, and the programme did not proceed to a phase 3 hair-loss indication. That the sponsor stopped short of approval is itself informative: it suggests the results were not strong enough to support a hair-loss claim. A further limitation is that these trials were conducted in men, so the findings cannot be extrapolated to women with hair loss.

Studies in other hair-loss conditions

The clearest human signal is not in pattern hair loss but in alopecia areata. Zaher and colleagues (2015, Dermatology) ran a pilot study in 30 adults with patchy scalp alopecia areata. Two patches on each patient were randomly assigned, one to mometasone furoate 0.1% cream once daily and the other to bimatoprost 0.03% solution twice daily, for three months. The authors reported that the bimatoprost-treated patches did significantly better on speed of response, percentage of regrowth and side effects, and concluded that bimatoprost represents a therapeutic option for scalp alopecia areata. It was a pilot study of 30 people and has not been replicated at scale.

A 2023 systematic review and meta-analysis of topical prostaglandin analogs for hair loss by Jiang and colleagues in Frontiers in Medicine pooled the available trials; a review of this kind is currently the best summary of a small and uneven evidence base, and it is where a reader should start rather than with any single study.

What we know (and don't) about its safety

In the scalp studies reported so far, the side effects have resembled those seen with use on the eyes or eyelashes: irritation, itching, and redness. The Latisse label warns that brown iris pigmentation from eye exposure is likely to be permanent, and it lists eyelid darkening, hair growth outside the treated area and periorbital fat atrophy. These matter for anyone applying it near the hairline, temples or eyes. Serious systemic effects have not been reported in those trials, but the trials were small and short, which is not the same as a clean long-term safety record. The scalp also differs from the eyelid in thickness, blood supply and pH, so tolerance on the eyelid cannot be assumed to carry over. For now, bimatoprost is not approved by the FDA for treating scalp hair loss.

Answering the original question: the published studies suggest bimatoprost can act on scalp follicles, but the data are not sufficient to make it a standard treatment for pattern hair loss. Unlike its approved use for eyelashes, its use in alopecia remains experimental, its long-term safety on the scalp is unknown, and larger, more diverse, published trials are needed to establish what it actually does.

User Experiences with Bimatoprost for Scalp Hair Growth

Bimatoprost, a synthetic prostamide originally developed to treat glaucoma and later used as Latisse for eyelash growth, is now being explored for scalp hair loss. Both the research and Tressless community discussions reflect cautious interest rather than confidence.

Bimatoprost is understood to work by extending the anagen (growth) phase of hair follicles. In laboratory and animal studies it stimulated scalp follicle growth and an earlier, longer entry into the growth phase. These effects are described as mediated through prostamide receptors, which are present in human scalp follicles. In the single 30-person alopecia areata pilot described above, the authors reported better results on the bimatoprost-treated patches than on the corticosteroid patches; that has not been replicated at scale. In androgenetic alopecia, by contrast, the registered trials were never published or taken forward, and in the larger one every bimatoprost formulation gained fewer hairs than minoxidil 5% (+6 to +13 versus +22 at 6 months).

Community Experiences

Tressless users are experimenting with bimatoprost, especially in custom formulations. One user reported 1% and 3% topical bimatoprost solutions and claimed better regrowth than with 5% minoxidil. That is 33 to 100 times the approved 0.03% strength, mixed outside any pharmacy standard, tested in no published scalp trial, and bimatoprost's known effects — skin and iris pigmentation changes, loss of fat around the eye socket, eye irritation — are documented on the label at 0.03%; no study has measured them at 1–3% on the scalp. The claim is one person's, with no photographs and no comparison. Another user considered combining bimatoprost with minoxidil in a serum, while others debated its role at the hairline. Some users prefer bimatoprost over latanoprost on perceived potency but remain concerned about orbital fat loss and eye pigmentation changes. Those effects are documented in ophthalmic use of the drug, and periorbital fat atrophy is a recognized consequence of long-term periocular application rather than a rare curiosity.

One post from early 2025 described a user starting bimatoprost alongside oral finasteride and minoxidil. The user was enthusiastic but acknowledged the known risks of prolonged use near the eyes. Sourcing is a recurring community theme: bimatoprost is a prescription product, and material obtained outside the pharmacy supply chain is not quality-controlled for strength or purity. Because bimatoprost is not approved for scalp use, there is no standardized dose or formulation for it, which is precisely why the community's self-made solutions vary so widely.

Bimatoprost is a prescription medicine and any scalp use is off-label and experimental. Talk to a doctor or pharmacist before starting, stopping or combining bimatoprost, particularly if you have an eye condition or are already using other hair-loss treatments.

References

Khidhir, K. G., Woodward, D. F., Farjo, N. P., Farjo, B. K., Tang, E. S., Wang, J. W., Picksley, S. M., & Randall, V. A. (2013). The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. FASEB Journal, 27(2), 557–567. PMID: 23104985. https://pmc.ncbi.nlm.nih.gov/articles/PMC3545535/

Zaher, H., Gawdat, H. I., Hegazy, R. A., & Hassan, M. (2015). Bimatoprost versus mometasone furoate in the treatment of scalp alopecia areata: a pilot study. Dermatology, 230(4), 308–313. PMID: 25765294. https://pubmed.ncbi.nlm.nih.gov/25765294/

Jiang, S., Hao, Z., Qi, W., Wang, Z., & Zhou, M. (2023). The efficacy of topical prostaglandin analogs for hair loss: a systematic review and meta-analysis. Frontiers in Medicine, 10, 1130623. PMID: 36999072. https://pmc.ncbi.nlm.nih.gov/articles/PMC10043424/

Barrón-Hernández, Y. L., & Tosti, A. (2017). Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opinion on Investigational Drugs, 26(4), 515–522. PMID: 28264599. https://pubmed.ncbi.nlm.nih.gov/28264599/

ClinicalTrials.gov. Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia. NCT01325337. https://clinicaltrials.gov/study/NCT01325337

ClinicalTrials.gov. A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA). NCT01904721. https://clinicaltrials.gov/study/NCT01904721

DailyMed. LATISSE (bimatoprost ophthalmic solution) 0.03% prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34f83d9d-2c64-463e-8a90-9a460fedfead

Reddit. (2021, October 5). Bimatoprost 1% solution on scalp. Retrieved from https://reddit.com/r/tressless/comments/q23mtm/bimatoprost_1_solution_on_scalp/

Reddit. (2025, January 31). Starting Bimatoprost! Hair time. Retrieved from https://reddit.com/r/tressless/comments/1ieoceg/starting_bimatoprost_hair_time/

Reddit. (2025, February 23). Topical bimatoprost or latanoprost. Retrieved from https://reddit.com/r/tressless/comments/1iwixkv/topical_bimatoprost_or_latanoprost/